Table 1.
Comparison of BL Characteristics, Changes During Antiviral Therapy, and Characteristics at FU HVPG Measurement Between Patients With CSPH at BL Who Had or Did Not Have an HVPG Decrease ≥ 10%
| Patient Characteristics | All, n = 67 | HVPG Decrease ≥ 10%, n = 40 | No HVPG Decrease ≥ 10%, n = 27 | P Value |
|---|---|---|---|---|
| Age, years | 54.5 ± 1.18 | 56.1 ± 1.4 | 52.2 ± 2 | 0.101 |
| Sex | ||||
| Male | 45 (67%) | 25 (63%) | 20 (74%) | 0.428 |
| Female | 22 (33%) | 15 (38%) | 7 (26%) | |
| BL BMI, kg × m−2 | 25.8 ± 0.6 | 25.8 ± 0.7 | 25.8 ± 1 | 0.966 |
| ≥25 kg × m−2 | 35 (52%) | 20 (50%) | 15 (56%) | 0.655 |
| ≥30 kg × m−2 | 12 (18%) | 7 (18%) | 5 (19%) | 1 |
| Δ BMI, kg × m−2 | 0.211 (2.366) | 0.106 (2.236) | 0.316 (2.564) | 0.691 |
| FU BMI, kg × m−2 | 26 ± 0.6 | 26 ± 0.75 | 26 ± 0.91 | 0.976 |
| ≥25 kg × m−2 | 38 (57%) | 23 (58%) | 15 (56%) | 0.875 |
| ≥30 kg × m−2 | 11 (16%) | 6 (15%) | 5 (19%) | 0.745 |
| Alcohol consumption | ||||
| Abstinent | 57 (85%) | 34 (85%) | 23 (85%) | 0.517 |
| Nonabstinent but below threshold* | 5 (7%) | 4 (10%) | 1 (4%) | |
| Above threshold* | 5 (7%) | 2 (5%) | 3 (11%) | |
| HCV genotype | ||||
| 1 | 45 (67%) | 25 (63%) | 20 (74%) | |
| 3 | 15 (22%) | 11 (28%) | 4 (27%) | 0.545 |
| 4 | 7 (10%) | 4 (10%) | 3 (11%) | |
| History of hepatic decompensation | 13 (19%) | 7 (18%) | 6 (22%) | 0.632 |
| BL CTP score, points | 6 (2) | 6 (2) | 7 (2) | 0.075 |
| Stage A | 43 (64%) | 30 (75%) | 13 (48%) | 0.037 |
| Stage B | 24 (36%) | 10 (25%) | 14 (52%) | |
| Δ CTP score, points | 0 (0) | 0 (0) | 0 (0) | 0.577 |
| FU CTP score, points | 6 (2) | 6 (1) | 6 (3) | 0.066 |
| BL MELD score, points | 9 (3) | 9 (3) | 10 (4) | 0.009 |
| Δ MELD score, points | 0 (2) | 0 (1) | −1 (2) | 0.521 |
| FU MELD score, points | 9 (2) | 8 (3) | 10 (4) | 0.027 |
| Varices | 33 (49%) | 17 (43%) | 16 (59%) | 0.178 |
| Small | 17 (52%) | 10 (59%) | 7 (44%) | 0.387 |
| Large | 16 (48%) | 7 (41%) | 9 (56%) | |
| NSBB treatment | 35 (52%) | 19 (48%) | 16 (59%) | 0.345 |
| BL HVPG, mm Hg | 16.2 ±0.5 | 15.8 ±0.6 | 16.7 ±0.9 | 0.395 |
| ≥16 mm Hg | 38 (57%) | 21 (53%) | 17 (63%) | 0.397 |
| Absolute Δ HVPG, mm Hg | −2.64 ± 0.46 | −5.1 ± 0.34 | 0.93 ± 0.49 | <0.001 |
| Relative Δ HVPG, % | −17.8 ± 2.9 | −33 ± 2.3 | 4.56 ± 2.61 | <0.001 |
| FU HVPG, mm Hg | 12 (7) | 10.5 (5) | 17 (11) | <0.001 |
| ≤5 mm Hg | 4 (6%) | 4 (10%) | 0 (0%) | <0.001 |
| 6‐9 mm Hg | 12 (18%) | 12 (30%) | 0 (0%) | |
| 10‐15 mm Hg | 29 (43%) | 19 (48%) | 10 (37%) | |
| ≥16 mm Hg | 22 (33%) | 5 (13%) | 17 (63%) | |
| BL liver stiffness, kPa† | 27.7 (25.4) | 27 (19.7) | 29.1 (24.1) | 0.269 |
| Absolute Δ liver stiffness, kPa† | −4.6 (11.9) | −6.8 (11) | −3.6 (19.7) | 0.004 |
| Relative Δ liver stiffness, %† | −18.1 (43.1) | −31.9 (35.9) | −8.22 (52.8) | <0.001 |
| FU liver stiffness, kPa† | 23 (26) | 19.1 (13.5) | 32.4 (27) | 0.002 |
| BL PLT, G × L−1 | 83 (49) | 100.5 (43) | 68 (49) | 0.004 |
| Absolute Δ PLT, G × L−1 | 7.16 ± 2.95 | 8.73 ± 3.99 | 4.85 ± 4.36 | 0.523 |
| Relative Δ PLT, G × L−1 | 8.11 (27.89) | 8.6 (24.79) | 3.03 (26.28) | 0.51 |
| FU PLT, G × L−1 | 89 (64) | 101 (62) | 77 (59) | 0.015 |
| BL VWF, %‡ | 293 (151) | 283 ± 15.7 | 311 ± 18 | 0.267 |
| Absolute Δ VWF, %‡ | −58 (90) | −83.3 ± 10 | −26.6 ± 8.8 | <0.001 |
| Relative Δ VWF, %‡ | −19.1 (26.4) | −30.1 (23.5) | −9.7 (19.9) | <0.001 |
| FU VWF, %‡ | 202 (141) | 179 (88) | 275 (198) | 0.003 |
| BL VITRO, %‡ | 3.38 (3.42) | 2.98 (2.41) | 4.64 (3.56) | 0.014 |
| Absolute Δ VITRO‡ | −0.791 (1.176) | −0.979 (1.442) | −0.382 (1.532) | 0.002 |
| Relative Δ VITRO, %‡ | −25.5 (38.6) | −34.1 (28.9) | −11.2 (43.7) | 0.013 |
| FU VITRO, %‡ | 2.4 (2.64) | 1.96 (1.96) | 3.31 (4.56) | 0.002 |
*
>30 g/day and >20 g/day for males and females, respectively.48
†
Information available in 64 patients.
‡
Information available in 65 patients.
Abbreviation: BMI, body mass index.